Department of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Cell Cycle. 2009 Nov 15;8(22):3695-701. doi: 10.4161/cc.8.22.9937. Epub 2009 Nov 27.
Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) mediates a plethora of physiological and pathological activities via interactions with a series of high affinity G protein-coupled receptors (GPCR). Both LPA receptor family members and autotaxin (ATX/LysoPLD), the primary LPA-producing enzyme, are aberrantly expressed in many human breast cancers and several other cancer lineages. Using transgenic mice expressing either an LPA receptor or ATX, we recently demonstrated that the ATX-LPA receptor axis plays a causal role in breast tumorigenesis and cancer-related inflammation, further validating the ATX-LPA receptor axis as a rich therapeutic target in cancer.
溶血磷脂酸(LPA,1-或 2-酰基-sn-甘油 3-磷酸)通过与一系列高亲和力 G 蛋白偶联受体(GPCR)相互作用,介导多种生理和病理活性。LPA 受体家族成员和自分泌运动因子(ATX/LysoPLD),即主要的 LPA 产生酶,在许多人类乳腺癌和其他几种癌症谱系中异常表达。使用表达 LPA 受体或 ATX 的转基因小鼠,我们最近证明 ATX-LPA 受体轴在乳腺癌发生和癌症相关炎症中起因果作用,进一步验证了 ATX-LPA 受体轴作为癌症的一个丰富治疗靶点。